Dear Editor,

The world had suffered pandemics of COVID-19 caused by SARS-CoV-2. At the time of writing, COVID-19 is still widely spreading in many countries and regions, and by June 14, 2022, totally 532,887,351 cases, including 6,307,021 deaths, were reported globally (WHO, https://covid19.who.int/table). Powerful measures, such as prophylactic and therapeutic interventions against the virus, are in urgent need for COVID-19 control and prevention.

The spike protein, which is expressed on the virus surface, is the key determinant of viral-host interaction (Ng et al., 2021) and mediates the virus entry, as the receptor-binding domain (RBD) of spike protein is responsible for binding to host receptor and the S2 subunit is responsible for membrane fusion (Harvey et al., 2021). Thus, interventions targeting SARS-CoV-2 spike protein are quite effective to fight against the virus. Spike protein binders, such as antibodies, miniproteins, peptide binders and DNA binders, have protective potential against SARS-CoV-2 infection (Gavor et al., 2020; Case et al., 2021; Singhal et al., 2021). With good accessibility, easy handling, easy modification, low immunogenicity, and low steric effect, peptide binders have been focused on. Peptides binding to spike protein with high affinity and specificity can contribute to developing diagnostic measures, therapeutic options, and learning virus entry (Ucar et al., 2021; Pomplun et al., 2021). However, at present, few peptides majorly targeting RBD had been identified by rational design, repurposing of anti-viral peptides, and selection (Zhao et al., 2020; Norman et al., 2021; Pei et al., 2021).

In this study, we selected peptide binders for SARS-CoV-2 spike S2 protein by using phage immunoprecipitation-sequencing (PhIP-Seq) technology with a phage-displayed random peptide library. Phage selection was usually based on panning technology combined with Sanger sequencing. However, useless results were often obtained since phages can not only bind to the target but also the nontarget subjects (including the container walls, the carriers, and irrelevant molecules), and target-unrelated phages can amplify to a large amount along with the panning progress. To decrease non-specific adsorption of phages and obtain more valuable information on protein-peptide interactions, we established a four-round alternant panning method combining amplicons next-generation sequencing (NGS) technology to select peptide binders for spike protein (Supplementary Fig. S1). As a huge amount of data would be produced by NGS, a “One-click” operation system running on MATLAB software has been developed to simplify the data processing. After normalizing the peptide reads into standardized scores, we compared scores between spike protein and negative control (NC), and 50 peptides were identified. After four rounds of selection, the peptide NFWISPKLAFAlGGGS (named Spep-1) showed significant enrichment (Supplementary Fig. S2). MEME Discovery of MEME suite (https://meme.suite.org/meme/tools/meme) was used to analyze the conserved motifs, and we found that most peptides appeared to share a similar motif with NFWISPKLAFAlGGGS. Interestingly, Spep-1 peptide showed the identical sequence with the motif (Fig. 1A).

Seven peptides were chosen and synthesized, and their binding ability to spike trimmer protein was evaluated by peptide-capture ELISA assay (Supplementary file). Results showed that Spep-1 peptide had an excellent binding ability to spike trimmer protein (Supplementary Fig. S3). Peptide-capture ELISA assay was conducted to determine the binding domain of Spep-1 on spike protein. RBD proteins, S1 protein, S2 protein, the ectodomain of spike trimer, and monomer proteins were incubated

Mengyuan Chen a,1, Shuizhen He b,1, Hualong Xiong c, Dongxu Zhang a, Shaojuan Wang a, Wangheng Hou a, Xiaomei Zhu a, Jin Wang a, Yang Huang a, Congming Hong a, Yubin Wu c, Ruoyao Qi c, Tianying Zhang a, Quan Yuan a, Tingdong Li a, Yixin Chen a, Shiyin Zhang a,* Shengxiang Ge a,* Jun Zhang a, Ningshao Xia a

a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, South Xiang’an Road, Xiamen, 361102, China
b Xiamen Haicang Hospital, Haiyu Road, Xiamen, 361026, China
c School of Life Sciences, Xiamen University, South Xiang’an Road, Xiamen, 361102, China

* Corresponding authors.
E-mail addresses: zhangshiyin@xmu.edu.cn (S. Zhang), sxge@xmu.edu.cn (S. Ge).

1 Mengyuan Chen and Shuizhen He contributed equally to this work.
with Spep-1 respectively and the binding complexes were detected by different antibodies (Supplementary file). The results showed that Spep-1 has a binding ability with spike trimer, monomer protein and S2 subunit (Fig. 1B). Further study showed that Spep-1 can also bind to spike protein of SARS-CoV-2 beta variant and SARS-CoV, but shows no binding activity to spike protein of SARS-CoV-2 delta variant and MERS-CoV.

To further study Spep-1’s specific target on S2 subunit, molecular docking analysis was also performed. In the docked complex, 18 amino acids of S2 subunit (Ile788, Try789, Lys790, Thr791, Pro792, Pro793, Ile794, Lys795, Ser803, Leu806, Asp808, Asp809, Ser813, Lys814, Gln872, Ser875 and Glu702) mediated interactions with Spep-1 peptide (Fig. 1C). Mutation energy analysis showed that Ile788, Lys790, Thr791, Lys795, Pro809, Lys814, Gln872 and Glu702 were the key amino acids (Supplementary Fig. S4).

To measure the affinity between Spep-1 peptide and SARS-CoV-2 spike proteins, we performed surface plasmon resonance (SPR) assays by using Biacore kinetic assays. Two analyses were conducted: in the first method, Spep-1 peptide was used as the analyte, while spike proteins were used as the analyte in the second method (Supplementary file). The Biacore kinetic assays showed that Spep-1 peptide bound to spike trimer protein and monomer protein with dissociation equilibrium constants $K_0$ of 9.28 $\times$ 10$^{-5}$ mol/L and 1.18 $\times$ 10$^{-4}$ mol/L respectively in the former assay (Supplementary Figs. S5A and S5B). In the latter assay, spike trimer and monomer protein bound to Spep-1 peptide with $K_0$ value of 1.70 $\times$ 10$^{-9}$ mol/L and 2.14 $\times$ 10$^{-7}$ mol/L respectively (Fig. 1D). S2 monomer protein also showed binding activity to Spep-1, however, the $K_0$ value only reached 5.61 $\times$ 10$^{-7}$ mol/L (Fig. 1D). This may be due to the conformational change of S2 protein we used.

Since spike proteins are bound to the immobilized Spep-1 peptide with high affinity, we further explored the potential usage of Spep-1. Spike trimer protein was mixed with SD-1 buffer and human serum collected from healthy donors to mimic the serum from the infected patient. Then the mixtures were incubated with biotin-labeled Spep-1 peptide or control peptide immobilized on SA beads. The captured proteins were analyzed by Western blotting using anti-SARS-CoV-2 spike RBD protein murine monoclonal antibody (Supplementary file). The results showed that Spep-1 could enrich spike trimer protein from human serum with high yields, while the control peptide had low yields in different matrices (Fig. 1E). Those results proved that Spep-1 could be used in the detection of SARS-CoV-2 spike protein in serum samples.

The SPR assay showed that the dissociation rate of spike protein was extremely low when Spep-1 was immobilized as the ligand and this prompted that Spep-1 can be used as an excellent capture molecule for spike antigen. Moreover, the binding of Spep-1 to spike protein caused little steric hindrance effect. Thus, sandwich ELISA assays based on Spep-1 capture/mAb detection system can be easily established and may have good performances. To verify the scheme, biotin-labeled Spep-1 or control peptides immobilized on SA coated plate was used as capture molecules for spike trimer or monomer protein, and three HRP conjugated mAbs 24C7, 24G1 and 24G2 that recognize different epitopes were randomly selected as detection antibodies. Buffers for diluting spiked serum samples and HRP-conjugated mAbs were screened, and the best detection performance was conducted by using ED13 buffer for diluting both (Supplementary Fig. S6).

Among the three detection systems, Spep-1/24C7 worked best and reached the detection limit of 0.76 pmol/L for both spike trimer protein and monomer protein in serum samples. The detection limit of 24G1 reached 6.96 pmol/L for spike trimer protein and 20.58 pmol/L for monomer protein, while the detection limit of 24G2 was 6.86 pmol/L for spike trimer protein and 0.76 pmol/L for monomer protein (Fig. 1F). Other studies also established immunoassays based on peptide binders, a high-affinity peptide binding to RBD of spike protein was selected by synthetic peptides-mass spectrometry technology which reached a lower limit of detection (LLOD) of 100 pmol/L spike RBD protein in spiked serum samples (Pomplon et al., 2021), and another RBD-binding cyclic peptide discovered by mRNA display technology reached an LLOD of 31.25 ng/mL (equivalent of 78.13 pmol/L) spike trimer protein (Norman et al., 2021). Compared with those researches, Spep-1 immunoassay increased the sensitivity by more than 100 times. Besides spike protein, the system can also detect SARS-CoV-2 pseudovirus in contrived serum samples (Fig. 1G).

In this study, by using the optimized PhIP-Seq methodology, we newly selected a peptide binding to the S2 subunit of SARS-CoV-2 spike protein and investigated the potential application of this peptide in clinical diagnostics. Since S2 subunit performs an important role in viral infusion and entry, it is also more conserved to be the target site for anti-viral inhibitor development (Ng et al., 2021). Our data showed that Spep-1 had a high affinity to SARS-CoV-2 spike trimer and monomer protein, with the $K_0$ values of 1.70 and 2.14 nmol/L (Spep-1 as the ligand in SPR analysis), which are quite high among the reported peptides (Mendoza-Figueroa et al., 2018; Hao et al., 2019; Pomplon et al., 2021; Rosseledt et al., 2021), suggesting that Spep-1 may have good application prospects, not only limited to SARS-CoV-2 spike antigen detection. In future studies, with rational modifications, Spep-1 might be used for studying the spatial and temporal distribution of S2 subunit during virus infusion, in vivo virus tracing, and drug delivery in biosafety laboratories. Although Spep-1 without modification didn’t show neutralizing activity based on SARS-CoV-2 pseudovirus neutralization assay established in our previous report (Xiong et al., 2020) (Supplementary Fig. S7), the data obtained in the current study proved that our PhIP-Seq platform could be used to select functional peptides. And we plan to select peptides with neutralizing activity against the RBD region of SARS-CoV-2 spike protein in the next step.

Footnotes

This work was supported by the National Key R&D Program of China (grant number 2020YFC0842600) and the National Natural Science Foundation of China (grant numbers 82041038 and 31730029). The authors declare that they have no conflict of interest. This article was approved by the Ethics Committee of School of Public Health Xiamen University (Approval number: SPhHRB-202101). Written consents were obtained from blood donors involved in the study.

All the data generated during the current study are included in the manuscript and supplementary material. Supplementary data to this article can be found online at https://doi.org/10.1016/j.virs.2022.07.001.
References

Case, J.B., Chen, R.E., Cao, L., Ying, B., Winkler, E.S., Johnson, M., Goreshnik, L., Pham, M.N., Shrihari, S., Kafal, N.M., Bailey, A.L., Xie, X., Shi, P.Y., Ravichandran, R., Carter, L., Stewart, L., Baker, D., Diamond, M.S., 2021. Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice. Cell Host Microbe 29, 1151–1161.e5.

Gavor, E., Choong, Y., Er, S., Sivaraman, H., Sivaraman, J., 2020. Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions. Trends Immunol. 41, 1006–1022.

Hao, J., Wang, F., Xing, G., Liu, Y., Deng, R., Zhang, H., Cheng, A., Zhang, G., 2019. Design and preliminary application of affinity peptide based on the structure of the porcine circovirus type II capsid (PCV2 cap). PeerJ 7, e8132.

Harvey, W., Carabelli, A., Jackson, B., Gupta, R., Thomson, E., Harrison, E., Ludden, C., Reeve, R., Rambaut, R., COVID-19 Genomics UK (COG-UK) Consortium, Peacock, S., Robertson, D., 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424.

Mendoza-Figueroa, J., Kvarnheden, A., M/C19endez-Lozano, J., Rodríguez-Negrete, E., Monteros, R., Soriano-García, M., 2018. A peptide derived from enzymatic digestion of globulins from amaranth shows strong affinity binding to the replication origin of tomato yellow leaf curl virus reducing viral replication in nicotiana benthamiana. Pestic. Biochem. Physiol. 145, 56–65.

Ng, K., Mobd-Ismail, N., Tan, Y., 2021. Spike S2 subunit: the dark horse in the race for prophylactic and therapeutic interventions against SARS-CoV-2. Vaccines (Basel) 9, 179.

Norman, A., Franck, C., Christie, M., Hawkins, H., Patel, K., Ashhurst, A., Aggarwal, A., Low, J., Siddiquee, R., Ashley, C., Stein, M., Triccas, J., Turville, S., Mackay, J., Passiourea, T., Payne, R., 2021. Discovery of cyclic peptide ligands to the SARS-CoV-2 spike protein using mrsa display. ACS Cent. Sci. 7, 1001–1008.

Pei, P., Qin, H., Chen, J., Wang, F., He, C., He, S., Hong, B., Liu, K., Qiao, R., Fan, H., Tong, Y., Chen, L., Luo, S., 2021. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. Briefings Bioinf. 22, bbab243.

Pomplun, S., Jbara, M., Quartararo, A., Zhang, G., Brown, J., Lee, Y., Ye, X., Hanna, S., Pentelute, B., 2021. De novo discovery of high-affinity peptide binders for the SARS-CoV-2 spike protein. ACS Cent. Sci. 7, 156–163.

Rosestedt, M., Velikyan, I., Rosenstrom, U., Estrada, S., Åberg, O., Weis, J., Westerland, C., Ingvast, S., Kongsren, O., Nordeinan, P., Eriksson, O., 2021. Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 1. Nucl. Med. Biol. 93, 54–62.

Singhal, S., Khanna, P., Khanna, L., 2021. Synthesis, comparative in vitro antibacterial, antioxidant and UV fluorescence studies of bis indole Schiff bases and molecular docking with ct-DNA and SARS-CoV-2 Mpro. Luminescence 36, 1531–1543.

Ucar, B., Aazar, T., Arayici, P., Derman, S., 2021. A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2. Nanotechnology. https://doi.org/10.1088/1361-6528/ac1c22.

Xiong, H., Wu, Y., Cao, J., Yang, R., Liu, Y., Ma, J., Qiao, X., Yao, X., Zhang, B., Zhang, M., Hou, W., Shi, Y., Xu, J., Zhang, L., Wang, S., Fu, B., Yang, T., Ge, S., Zhang, J., Yuan, Q., Huang, B., Li, Z., Zhang, T., Xia, N., 2020. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg. Microb. Infect. 9, 2105–2113.

Zhao, H., To, K., Sze, K., Yung, T., Biam, M., Lam, H., Yeung, M., Li, C., Chu, H., Yuen, K., 2020. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. Nat. Commun. 11, 4252.